Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Royalty Pharma

RPRXNasdaqUSLarge cap
  • Russell 1000

What Royalty Pharma is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $2.54 billion, up 10.0% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to December 31, 2025: $1.23 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 5, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 11, 2026): 0 risk factors added, 7 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $13.2 million on the open market.SEC Form 4
  • 646 institutional managers reported a position at June 30, 2026 (+53 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 1.U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

Royalty Pharma's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Bonds priced, last 12 months

None

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

PricedAmountCouponMaturesSpreadYield
Sep 2, 2025$600M4.450%2031 (6y)+93bp4.676%
Sep 2, 2025$900M5.200%2035 (10y)+118bp5.463%
Sep 2, 2025$500M5.950%2055 (30y)+128bp6.260%
Jun 3, 2024$500M5.150%2029 (5y)+100bp5.421%
Jun 3, 2024$500M5.400%2034 (10y)+127bp5.674%
Jun 3, 2024$500M5.900%2054 (30y)+152bp6.071%

From the pricing term sheets Royalty Pharma filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Royalty Pharma: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Royalty Pharma: revenue, trailing twelve months

$ billions, from SEC filings

$2.5BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Royalty Pharma: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$1.2BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Royalty Pharma: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2022
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Royalty Pharma: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Royalty Pharma: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

4.2Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Royalty Pharma: guidance raised minus lowered

Guidance Ledger statements by quarter

1.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Royalty Pharma: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.70Data to Aug 2026
ImageDataPalanor calculation
Business

Royalty Pharma: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.80Data to Aug 2026
ImageDataPalanor calculation
Business

Royalty Pharma: risk factors added per annual report

New Item 1A risk factors in each 10-K

0.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Royalty Pharma: H-1B filings certified

Labor Condition Applications by quarter received

1.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Royalty Pharma: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$13.2MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Royalty Pharma: institutional holders

Managers reporting a position on Form 13F, by quarter

646.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Jun 4, 20268-K
    Shareholder vote resultsItem 5.07
  2. May 28, 20268-K
    Material agreement signedItem 1.01
  3. Feb 11, 202610-K
    Annual report (10-K)0 risk factors added, 7 removed
  4. Dec 22, 20258-K
    Director or officer changeItem 5.02
  5. Sep 16, 20258-K
    Material agreement signedItem 1.01
  6. Aug 13, 20258-K
    Director or officer changeItem 5.02
  7. Jul 17, 20258-K
    Director or officer changeItem 5.02
  8. May 19, 20258-K
    Material agreement signedItem 1.01
  9. May 19, 20258-K
    Acquisition or sale completedItem 2.01
  10. May 19, 20258-K
    Director or officer changeItem 5.02
  11. May 12, 20258-K
    Shareholder vote resultsItem 5.07
  12. Apr 11, 20258-K
    Material agreement signedItem 1.01
  13. Apr 10, 20258-K
    Director or officer changeItem 5.02
  14. Feb 12, 202510-K
    Annual report (10-K)4 risk factors added, 1 removed
  15. Jan 10, 20258-K
    Material agreement signedItem 1.01
  16. Dec 31, 20248-K
    Material agreement signedItem 1.01
  17. Feb 15, 202410-K
    Annual report (10-K)0 risk factors added, 2 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Hims & Hers Health HIMS$2.6B$0.1BJun 30, 2026
Bio-Rad Laboratories BIO$2.6B$0.3BJun 30, 2026
Chemed Corporation CHE$2.6B$0.3BJun 30, 2026
Exelixis EXEL$2.4B$1.2BJul 3, 2026
Natera NTRA$2.7B$0.1BJun 30, 2026
Medpace MEDP$2.8B$0.7BJun 30, 2026
Envista NVST$2.9B$0.3BJul 3, 2026
Teleflex TFX$2.3B$0.2BJun 30, 2026

Identity

SEC CIK
1802768

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.